Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FOCL
FocalTherics
$4.76
+2.8%		$5.39
$1.30
▼
$6.40
$178.41M-0.04154,419 shs355,833 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$1.62
+2.5%		$1.55
$1.26
▼
$6.87
$62.79M1.62125,715 shs117,494 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$67.02
-1.3%		$61.49
$23.47
▼
$68.99
$213.98M0.0291,360 shs24,164 shs
Avita Medical Inc. stock logo
RCEL
Avita Medical
$7.85
-2.0%		$4.84
$3.22
▼
$8.55
$241.60M1.86638,533 shs270,938 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FOCL
FocalTherics
0.00%-23.47%-12.50%+475,999,900.00%+475,999,900.00%
Nyxoah SA stock logo
NYXH
Nyxoah
0.00%+10.20%0.00%-47.40%-74.33%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.00%+2.23%+13.44%+13.08%+58.29%
Avita Medical Inc. stock logo
RCEL
Avita Medical
0.00%+1.03%+57.63%+72.15%+36.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FOCL
FocalTherics
$4.76
+2.8%		$5.39
$1.30
▼
$6.40
$178.41M-0.04154,419 shs355,833 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$1.62
+2.5%		$1.55
$1.26
▼
$6.87
$62.79M1.62125,715 shs117,494 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$67.02
-1.3%		$61.49
$23.47
▼
$68.99
$213.98M0.0291,360 shs24,164 shs
Avita Medical Inc. stock logo
RCEL
Avita Medical
$7.85
-2.0%		$4.84
$3.22
▼
$8.55
$241.60M1.86638,533 shs270,938 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FOCL
FocalTherics
0.00%-23.47%-12.50%+475,999,900.00%+475,999,900.00%
Nyxoah SA stock logo
NYXH
Nyxoah
0.00%+10.20%0.00%-47.40%-74.33%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.00%+2.23%+13.44%+13.08%+58.29%
Avita Medical Inc. stock logo
RCEL
Avita Medical
0.00%+1.03%+57.63%+72.15%+36.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FOCL
FocalTherics
2.40
Hold$7.7562.82% Upside
Nyxoah SA stock logo
NYXH
Nyxoah
2.25
Hold$5.26224.81% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2.67
Moderate Buy$70.004.45% Upside
Avita Medical Inc. stock logo
RCEL
Avita Medical
2.57
Moderate Buy$8.255.10% Upside

Current Analyst Ratings Breakdown

Latest NYXH, RCEL, FOCL, and PDEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
FOCL
FocalTherics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$4.00
8/7/2026
Avita Medical Inc. stock logo
RCEL
Avita Medical
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$7.00
8/6/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/6/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$2.31
8/6/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$7.00 ➝ $6.00
8/6/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$4.00
7/17/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/17/2026
FOCL
FocalTherics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOutperform$15.00
7/17/2026
FOCL
FocalTherics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/9/2026
Nyxoah SA stock logo
NYXH
Nyxoah
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$2.85
7/1/2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FOCL
FocalTherics
$70.53M2.53N/AN/A$0.52 per share9.15
Nyxoah SA stock logo
NYXH
Nyxoah
$11.33M5.54N/AN/A$1.43 per share1.13
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$66.59M3.21$3.14 per share21.37$11.23 per share5.97
Avita Medical Inc. stock logo
RCEL
Avita Medical
$71.61M3.37N/AN/A($0.55) per share-14.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FOCL
FocalTherics
-$29.25M-$1.03N/AN/AN/A-56.26%-175.45%-44.72%8/27/2026 (Estimated)
Nyxoah SA stock logo
NYXH
Nyxoah
-$101.92M-$2.52N/AN/AN/A-443.16%-178.90%-81.83%N/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$8.98M$3.6223.6024.11N/A16.08%22.78%14.30%9/3/2026 (Estimated)
Avita Medical Inc. stock logo
RCEL
Avita Medical
-$48.59M-$1.44N/AN/AN/A-56.96%N/A-78.53%N/A

Latest NYXH, RCEL, FOCL, and PDEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/3/2026Q4 2026
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.67N/AN/AN/A$19.20 millionN/A
8/27/2026Q2 2026
FOCL
FocalTherics
-$0.2287N/AN/AN/A$22.48 millionN/A
8/14/2026Q2 2026
FOCL
FocalTherics
-$0.20-$0.39-$0.19-$0.39N/A$13.20 million
8/6/2026Q2 2026
Nyxoah SA stock logo
NYXH
Nyxoah
-$0.47-$0.67-$0.20-$0.66$8.64 million$8.76 million
8/6/2026Q2 2026
Avita Medical Inc. stock logo
RCEL
Avita Medical
-$0.2928-$0.25+$0.0428-$5.00$20.25 million$21.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FOCL
FocalTherics
N/AN/AN/AN/AN/A
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
Avita Medical Inc. stock logo
RCEL
Avita Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FOCL
FocalTherics
1.79
1.34
0.99
Nyxoah SA stock logo
NYXH
Nyxoah
0.44
2.38
2.31
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.32
3.67
2.14
Avita Medical Inc. stock logo
RCEL
Avita Medical
N/A
0.41
0.34

Institutional Ownership

CompanyInstitutional Ownership
FOCL
FocalTherics
62.74%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
Avita Medical Inc. stock logo
RCEL
Avita Medical
27.66%

Insider Ownership

CompanyInsider Ownership
FOCL
FocalTherics
10.10%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
45.90%
Avita Medical Inc. stock logo
RCEL
Avita Medical
2.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
FOCL
FocalTherics
23037.48 million33.70 millionN/A
Nyxoah SA stock logo
NYXH
Nyxoah
11038.76 millionN/ANot Optionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1403.19 million1.73 millionNot Optionable
Avita Medical Inc. stock logo
RCEL
Avita Medical
13030.78 million30.09 millionOptionable

Recent News About These Companies

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-raises-2026-revenue-outlook-as-q2-sales-climb-18-2026-08-16/
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-targets-q4-2025-cash-flow-breakeven-as-revenue-growth-builds-2026-08-16/
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript
August 13 at 8:16 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/avita-medical-rcel-q2-2026-221541448.html
AVITA Medical to Host Investor Webinar Briefing
August 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/09/3341503/0/en/avita-medical-to-host-investor-webinar-briefing.html
Avita Medical (NASDAQ:RCEL) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-nasdaqrcel-releases-quarterly-earnings-results-beats-estimates-by-004-eps-2026-08-08/
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
August 7, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/avita-medical-reports-second-quarter-results-raises-2026-revenue-guidance-and-expects-fourth-quarter-cash-flow-breakeven-1036422648
Avita Medical shares surge after record second-quarter performance
August 7, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/avita-medical-shares-surge-after-record-second-quarter-performance/ar-AA29BFql
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341101/0/en/avita-medical-announces-participation-at-canaccord-genuity-growth-conference.html
Avita Medical Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-q2-earnings-call-highlights-2026-08-07/
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932718-avita-medical-inc-rcel-q2-2026-earnings-call-transcript
Avita Medical (RCEL) Projected to Post Quarterly Earnings on Thursday
August 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30942796
Wall Street Zen Upgrades Avita Medical (NASDAQ:RCEL) to "Hold"
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-avita-medical-nasdaqrcel-to-hold-2026-08-02/
Avita Medical (RCEL) Projected to Announce Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-rcel-projected-to-announce-earnings-on-thursday-2026-07-30/
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from Brokerages
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-inc-nasdaqrcel-receives-consensus-recommendation-of-hold-from-brokerages-2026-07-25/
Avita Medical (NASDAQ:RCEL) Downgraded to "Sell" Rating by Wall Street Zen
July 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avita-medical-nasdaqrcel-downgraded-to-sell-rating-by-wall-street-zen-2026-07-25/
Analysts Are Neutral on These Healthcare Stocks: Cencora (COR), Avita Medical (RCEL)
July 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TEM/pressreleases/3411481/analysts-are-neutral-on-these-healthcare-stocks-cencora-cor-avita-medical-rcel/
AVITA Medical (RCEL) Stock Sees Fair Value Lift As Analysts Back RECELL Momentum
July 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/avita-medical-rcel-stock-sees-161417777.html
AVITA Medical to Announce Second Quarter 2026 Financial Results
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3327257/0/en/avita-medical-to-announce-second-quarter-2026-financial-results.html
Avita Medical (RCEL) Upgraded to Buy: Here's Why
July 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2947957/avita-medical-rcel-upgraded-to-buy-here-s-why?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2947957
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
June 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/avita-medical-highlights-first-u-k-clinical-experience-with-recell-go-at-british-burn-association-annual-meeting-1036259517
Avita Medical (NASDAQ:RCEL) Director Purchases $20,800.00 in Stock
June 11, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rcel-insider-buying-and-selling-2026-06-11/

New MarketBeat Followers Over Time

Media Sentiment Over Time

FocalTherics NASDAQ:FOCL

$4.76 +0.13 (+2.81%)
As of 08/14/2026 04:00 PM Eastern

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Nyxoah stock logo

Nyxoah NASDAQ:NYXH

$1.62 +0.04 (+2.53%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$1.62 +0.00 (+0.31%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$67.02 -0.88 (-1.30%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$67.05 +0.03 (+0.04%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Avita Medical stock logo

Avita Medical NASDAQ:RCEL

$7.85 -0.16 (-2.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$8.01 +0.16 (+1.99%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas